TW202328186A - 抗ｈｅｒ２抗體及其使用方法 - Google Patents

抗ｈｅｒ２抗體及其使用方法 Download PDF

Info

Publication number
TW202328186A
TW202328186A TW111132034A TW111132034A TW202328186A TW 202328186 A TW202328186 A TW 202328186A TW 111132034 A TW111132034 A TW 111132034A TW 111132034 A TW111132034 A TW 111132034A TW 202328186 A TW202328186 A TW 202328186A
Authority
TW
Taiwan
Prior art keywords
seq
amino acid
heavy chain
acid sequence
polypeptide
Prior art date
Application number
TW111132034A
Other languages
English (en)
Chinese (zh)
Inventor
阿比拉 班迪奧帕迪耶
艾麗莎 傑恩 克萊門斯
金度真
蜜雪兒 Ｅ 皮佐
璐 山
理查德 二世 西奧利斯
家恒 唐
Original Assignee
美商戴納立製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商戴納立製藥公司 filed Critical 美商戴納立製藥公司
Publication of TW202328186A publication Critical patent/TW202328186A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW111132034A 2021-08-25 2022-08-25 抗ｈｅｒ２抗體及其使用方法 TW202328186A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163237104P 2021-08-25 2021-08-25
US63/237,104 2021-08-25

Publications (1)

Publication Number Publication Date
TW202328186A true TW202328186A (zh) 2023-07-16

Family

ID=85322213

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111132034A TW202328186A (zh) 2021-08-25 2022-08-25 抗ｈｅｒ２抗體及其使用方法

Country Status (12)

Country Link
US (2) US20250136713A1 (https=)
EP (1) EP4392458A4 (https=)
JP (1) JP2024534118A (https=)
KR (1) KR20240052019A (https=)
CN (1) CN117980342A (https=)
AR (1) AR126873A1 (https=)
AU (1) AU2022333088A1 (https=)
CA (1) CA3229542A1 (https=)
IL (1) IL311003A (https=)
MX (1) MX2024002406A (https=)
TW (1) TW202328186A (https=)
WO (1) WO2023028543A2 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
AU2014357292B2 (en) * 2013-11-27 2020-06-25 Zymeworks Bc Inc. Bispecific antigen-binding constructs targeting HER2
SG11201608192SA (en) * 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
EP3609580A4 (en) * 2017-04-09 2021-03-24 Combio Pharmaceutical, Inc. COMMON LIGHT CHAIN BIPARATOPIC AND MULTIPARATOPIC ANTIBODIES AND METHOD OF USE

Also Published As

Publication number Publication date
EP4392458A2 (en) 2024-07-03
AR126873A1 (es) 2023-11-22
CN117980342A (zh) 2024-05-03
WO2023028543A3 (en) 2023-06-08
MX2024002406A (es) 2024-04-03
US20250136713A1 (en) 2025-05-01
IL311003A (en) 2024-04-01
CA3229542A1 (en) 2023-03-02
KR20240052019A (ko) 2024-04-22
EP4392458A4 (en) 2025-11-19
WO2023028543A2 (en) 2023-03-02
AU2022333088A1 (en) 2024-03-07
US20260109781A1 (en) 2026-04-23
JP2024534118A (ja) 2024-09-18

Similar Documents

Publication Publication Date Title
JP6432121B2 (ja) Ｐｄｌ−１抗体、その医薬組成物及びその使用
JP7818042B2 (ja) 抗ｈｅｒ２ポリペプチド及びそれらの使用の方法
US20230192887A1 (en) Engineered anti-her2 bispecific proteins
JP7495409B2 (ja) 改善された抗ｆｌｔ３抗原結合タンパク質
CN113454120A (zh) 针对人免疫检查点CEACAM1（CD66a）的拮抗剂抗体及其制剂，试剂盒，和使用方法
CN120239710A (zh) 抗ccr8抗体及其用途
JP2025525885A (ja) Ｇｕｃｙ２ｃとｃｄ３に特異的に結合する抗原結合分子及びその医薬的使用
US20260109781A1 (en) Anti-her2 antibodies and methods of use thereof
US20240392035A1 (en) Engineered anti-her2 bispecific proteins
HK40110414A (zh) 抗her2抗体及其使用方法
US20260109769A1 (en) Pd-1 bnding proteins, vegf and pd-1 bispecific binding proteins, compositions, and methods of use
WO2026067461A1 (en) Multispecific antibody protein and uses thereof
RU2830982C2 (ru) Улучшенные анти-flt3 антигенсвязывающие белки
HK40084724A (en) Engineered anti-her2 bispecific proteins
JP2026505164A (ja) 抗ｃｍｅｔ抗体及びその使用方法
WO2024184811A1 (en) Anti-cd3 multispecific antibodies and methods of use
EP4676961A1 (en) Anti-cd3 multispecific antibodies and methods of use
HK40119369A (zh) 抗SIRP α抗体及其用途
HK40076375B (zh) 抗SIRPα抗体及其用途